Patent · US Active

Formulations of tegavivint and related compounds

US12246010B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignee

Iterion Therapeutics, Inc. · US

Inventors

Steven David Dykstra · Apex, US
Henry Havel · Indianapolis, US
Stephen Horrigan · Gaithersburg, US
Roger G. Harrison · Farnborough, GB
Jeffrey John Larson · Coeur d'Alene, US
Jonathan Northrup · Houston, US
Theodore Laslo · Wind Gap, US
Garry Thomas Gwozdz · Nazareth, US

Key dates

Filing date	Feb 25, 2022
Grant date	Mar 11, 2025
Priority date	—
Expiry date	Feb 25, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/18
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.